1. Home
  2. RDHL vs GOVX Comparison

RDHL vs GOVX Comparison

Compare RDHL & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

N/A

Current Price

$0.85

Market Cap

4.0M

Sector

Health Care

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$0.59

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDHL
GOVX
Founded
2009
2001
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
3.8M
IPO Year
2012
1996

Fundamental Metrics

Financial Performance
Metric
RDHL
GOVX
Price
$0.85
$0.59
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
2.1M
584.9K
Earning Date
04-27-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,489,145.00
Revenue This Year
$381.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.12
52 Week High
$2.79
$4.40

Technical Indicators

Market Signals
Indicator
RDHL
GOVX
Relative Strength Index (RSI) 68.84 37.87
Support Level $0.76 $0.14
Resistance Level $0.91 $0.85
Average True Range (ATR) 0.09 0.08
MACD 0.04 0.02
Stochastic Oscillator 28.43 7.63

Price Performance

Historical Comparison
RDHL
GOVX

About RDHL Redhill Biopharma Ltd.

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: